Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics, Inc. has successfully completed a registered direct offering, raising approximately $4.5 million through the sale of 1,363,637 shares of its common stock. The transaction, which was finalized on June 12, 2026, also includes the potential for an additional $12 million in gross proceeds through the exercise of warrants associated with the offering. Rodman & Renshaw LLC served as the exclusive placement agent for this fundraising initiative.

Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and other areas with significant unmet medical needs. The company’s lead product candidate, (Z)-endoxifen, is currently undergoing clinical trials across various settings. The funds raised from this offering are earmarked for the clinical development of Atossa's product candidates, as well as for working capital and general corporate purposes, which are critical for sustaining operations and advancing its research initiatives.

The offering comprises Series A and Series B warrants, which provide investors with the option to purchase additional shares of common stock. The Series A warrants are valid for a period of five and a half years, while the Series B warrants are short-term, expiring after two years. The exercise of these warrants could significantly enhance Atossa's financial position, although the company has indicated that there is no guarantee that the warrants will be exercised.

This fundraising comes at a time when the biopharmaceutical sector is experiencing heightened activity, particularly in the oncology space. The demand for innovative treatments continues to grow, driven by advancements in technology and an increasing focus on personalized medicine. Companies like Atossa are well-positioned to capitalize on these trends, especially as they develop therapies that address critical gaps in current treatment options.

The successful completion of this offering underscores the ongoing investor interest in biopharmaceutical companies, particularly those with promising clinical candidates. As Atossa Therapeutics moves forward with its development plans, the additional capital will be vital in navigating the complexities of clinical trials and regulatory approvals. Overall, this transaction reflects a broader trend within the sector, where companies are actively seeking funding to support their innovative pipelines and enhance shareholder value.